ATS 2024 Final Program

Click on the session title to view the speakers

166

MONDAY • MAY 20

P34 Relevance of BKCa Channels in Pulmonary Endothelial Dysfunction P35 Loss of WWOX Modulates Cell Cycle Progression in Human Pulmonary Arterial Smooth Muscle Cells P36 Cilostazol Protects Against Lung Endothelial Barrier Dysfunction Caused by MRSA P37 The Mitochondrial Genome:at the Crossroads of NLRP3-mediated Inflammation and Recovery P38 NAD+-Dependent Motility of Circulating Human Neonatal Endothelial Colony-forming Cells P39 Developing a Phase Separation Assay to Study PPM1B Signaling P40 Lung Endothelial Cell Barrier Protection by Estrogen Is Associated With Increased Expression of Claudin-5 and Sphingosine Kinase-1 P41 MicroRNA-224 Orchestrates the BMP Pathway and Represents a New Therapeutic Target for Pulmonary Hypertension P42 A MicroRNA-based Therapeutic Approach for Pulmonary Arterial Hypertension P43 Extracellular Cyclic AMP Suppresses Pulmonary Arterial Hypertension-induced Ventricular Arrhythmias P44 A Monoclonal Antibody Targeting the ZIP12 Transporter Attenuates Severe Experimental Pulmonary Arterial Hypertension B63 BRONCHOPULMONARY DYSPLASIA AND DEVELOPMENTAL LUNG DISEASE 9:15 a.m. - 4:15 p.m. San Diego Convention Center Area G (Hall A-B2, Ground Level) Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P713 Bronchopulmonary Dysplasia in Very Low Birth Weight Asian American, Native Hawaiian, and Pacific Islander Infants in California BASIC • CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

P714 Volatile Organic Compounds and the Relevance of Correcting for Background Signals in the Early Prediction of Bronchopulmonary Dysplasia in Preterm Infants P715 Efforts to Reduce Inhaled Corticosteroid Use at NICU Discharge for Infants With BPD Resulted in Those Infants Being Started on Inhaled Corticosteroids Later in Infancy P716 Nintedanib, An Anti-fibrotic Drug, Preserves Lung Alveolar and Vascular Growth and Prevents Pulmonary Hypertension in an Experimental Model of Hyperoxia-induced Lung Injury P717 Characterizing Outpatient Diuretic Therapy in Children With Bronchopulmonary Dysplasia P718 Factors Related to Tracheostomy Timing in Moderate to Severe Bronchopulmonary Dysplasia P719 Predictive Markers for Tracheostomy and Long-term Ventilation (LTV) in Infants With Bronchopulmonary Dysplasia (BPD) P720 Use of Long-Term Home Ventilation for Preterm Infants With Bronchopulmonary Dysplasia in British Columbia: A Retrospective Cohort Study P721 The Effect of Catheter Thickness on Work of Breathing in Premature Newborns P722 Injury Response in the Developing Lung Mesenchyme: Role of Chromosomal Versus Gonadal Sex P723 High Comorbidity Rates in Congenital Lobar Emphysema and the Impact on Clinical Presentation P724 Risk Factors for Long Term Mortality in Children With Congenital Diaphragmatic Hernia P725 A Macrophage (Drug Product)- Delivery Device (Bronchoscope) Compatibility Study P726 Surgical Approach to Congenital Lung Malformations: A Case Study at Hospital Universitario San Ignacio P727 Case Report: Calcifying Fibrous Pseudotumor of the Lung in an 8-year Old P728 Pulmonary Infantile Hemangioma in a Patient With Cardiac and Liver Malformations P729 Acquired Tracheoesophageal Fistula in Infants After Tracheostomy Tube Placement

ATS 2024 Conference Program • San Diego, CA